Arbutus Biopharma Corp Net Fee Amt
Arbutus Biopharma Corp (ABUS) had Net Fee Amt of $31.76 thousand as of 2026-08-21, per its SC TO-I filed 2026-08-24.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-24
- 2026-08-21: Net Fee Amt $31.76K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-21 | $31.76K SC TO-I · filed 2026-08-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |